NCT05010265 An Ethical Approach to Detecting Covert Consciousness
| NCT ID | NCT05010265 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Disorder of Consciousness |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2022-02-01 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2022-02-01 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop an ethical approach to developing and deploying novel neurotechnologies to aid in the detection of consciousness and prediction of recovery after brain injury.
Eligibility Criteria
Inclusion Criteria: * Patients with prior or ongoing participation as subject in a research study using neurotechnologies for diagnosis and prognosis of disorders of consciousness (DoC) at Mass General Brigham * Patients capable of understanding and answering questions in English * Patients cble to provide informed consent * Patients for whom MRI / EEG are administered for clinical detection of consciousness and/or neuroprognostication * Family member or surrogate caregiver of patients who previously participated or are currently participating in a research study using neurotechnologies for diagnosis and prognosis of DoC at Mass General Brigham. * Family Members / Surrogates capable of understanding and answering questions in English * Family Members / Surrogates able to provide informed consent * Family member or surrogate caregiver of patients for whom MRI / EEG are administered for clinical detection of consciousness and/or neuroprognostication * Research Investigators involved with research responsibilities in designing or testing neurotechnologies on patients with DoC. * Clinicians with clinical responsibilities caring for patients in behaviorally unresponsive state, defined as coma, vegetative state (VS), and low-level minimally conscious state (MCS). * Selected leaders and advisors (Community and Thought Leaders) from brain injury associations and advocacy organizations, and policy-makers involved in decision-making impacting patients with DoC. Exclusion Criteria: None
Contact & Investigator
Michael Young, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT05010265 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Disorder of Consciousness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05010265 currently recruiting?
Yes, NCT05010265 is actively recruiting participants. Contact the research team at Michael.Young@MGH.HARVARD.EDU for enrollment information.
Where is the NCT05010265 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05010265 clinical trial?
NCT05010265 is sponsored by Massachusetts General Hospital. The principal investigator is Michael Young, MD at Massachusetts General Hospital. The trial plans to enroll 70 participants.